15.63
Schlusskurs vom Vortag:
$15.75
Offen:
$15.71
24-Stunden-Volumen:
398.28K
Relative Volume:
0.61
Marktkapitalisierung:
$5.53B
Einnahmen:
$4.89B
Nettoeinkommen (Verlust:
$-263.00M
KGV:
-20.21
EPS:
-0.7734
Netto-Cashflow:
$-167.84M
1W Leistung:
+3.30%
1M Leistung:
+2.90%
6M Leistung:
+29.71%
1J Leistung:
-24.42%
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BLCO
Bausch Lomb Corp
|
15.63 | 5.57B | 4.89B | -263.00M | -167.84M | -0.7734 |
![]()
ISRG
Intuitive Surgical Inc
|
462.74 | 164.35B | 9.15B | 2.63B | 1.99B | 7.1661 |
![]()
BDX
Becton Dickinson Co
|
189.03 | 54.75B | 21.39B | 1.61B | 2.55B | 5.5609 |
![]()
RMD
Resmed Inc
|
268.22 | 39.61B | 5.15B | 1.40B | 1.65B | 9.5082 |
![]()
ALC
Alcon Inc
|
75.76 | 37.31B | 10.03B | 1.07B | 1.39B | 2.1549 |
![]()
WST
West Pharmaceutical Services Inc
|
279.39 | 19.77B | 2.96B | 487.70M | 344.00M | 6.6758 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-10-01 | Eingeleitet | Goldman | Neutral |
2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
2024-07-10 | Eingeleitet | Raymond James | Outperform |
2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
2023-12-12 | Eingeleitet | Stifel | Hold |
2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2023-03-09 | Eingeleitet | Needham | Hold |
2022-12-21 | Eingeleitet | Barclays | Equal Weight |
2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
2022-06-06 | Eingeleitet | Citigroup | Buy |
2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
2022-05-31 | Eingeleitet | Goldman | Neutral |
2022-05-31 | Eingeleitet | Guggenheim | Buy |
2022-05-31 | Eingeleitet | JP Morgan | Neutral |
2022-05-31 | Eingeleitet | Jefferies | Buy |
2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Published on: 2025-10-21 20:10:31 - newser.com
Is Bausch + Lomb Corporation (S2L) stock a momentum leaderOptions Play & Risk Controlled Stock Pick Alerts - newser.com
BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating, Maintains Target Price $13 - 富途牛牛
Is Bausch + Lomb Corporation (S2L) stock worth buying before Fed actionWeekly Trading Summary & Fast Entry Momentum Trade Alerts - newser.com
Will Bausch + Lomb Corporation stock announce special dividendGap Down & Weekly Return Optimization Plans - newser.com
Applying big data sentiment scoring on Bausch + Lomb CorporationJuly 2025 Opening Moves & Capital Protection Trade Alerts - newser.com
Potential CooperVision–Bausch + Lomb merger floated by investor - Rochester Business Journal
Why global investors buy Bausch + Lomb Corporation stockWeekly Market Summary & Fast Momentum Stock Entry Tips - newser.com
Will Bausch + Lomb Corporation stock benefit from commodity supercycleQuarterly Trade Report & Weekly Setup with High ROI Potential - newser.com
Activist investor Jana Partners takes stake in Cooper Companies, sources say - Reuters
Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb - Benzinga
Is Bausch + Lomb Corporation stock safe for conservative investorsJuly 2025 Volume & Free Community Consensus Stock Picks - newser.com
3 Stocks Under $50 We Steer Clear Of - The Globe and Mail
Bausch + Lomb Corporation (BLCO) Receives a Hold from Stifel Nicolaus - The Globe and Mail
What does recent volatility data suggest for Bausch + Lomb Corporation2025 Short Interest & Long-Term Growth Portfolio Plans - newser.com
Contact Lenses Market Trends, Shares, Strategies and Growth Analysis Report (2025-2034) Featuring Alcon Vision, Bausch & Lomb, J&J Vision Care, CooperVision, Essilor International and More - GlobeNewswire Inc.
Earnings call transcript: Bausch + Lomb sees revenue growth in Q2 2025 - Investing.com India
Bausch + Lomb Q2 2025 slides: Revenue grows 3% as company raises full-year guidance - Investing.com Australia
Earnings call transcript: Bausch + Lomb sees revenue growth in Q2 2025 By Investing.com - Investing.com South Africa
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Stifel reiterates Buy rating on Bausch & Lomb stock, maintains $12 price target - Investing.com UK
Bausch + Lomb (NYSE:BLCO): Evaluating Valuation After Recent Earnings and Share Price Moves - Yahoo Finance
Bausch + Lomb Corporation (BLCO) Stock Forecasts - Yahoo Finance
Analyzing drawdowns of Bausch + Lomb Corporation with statistical toolsMarket Movement Recap & Community Driven Trade Alerts - newser.com
Bausch + Lomb's (BLCO) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
Bausch + Lomb (NYSE:BLCO) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
What drives Bausch Lomb Corporation stock priceVolume Spike Alerts & Fast Growing Capital Growth - earlytimes.in
Bausch + Lomb Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
Can Bausch + Lomb Corporation (S2L) stock deliver strong annual returnsShare Buyback & Step-by-Step Trade Execution Guides - newser.com
Barclays Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $16 - 富途牛牛
Assessing Bausch + Lomb (NYSE:BLCO) Valuation as Goldman Sachs Brings New Spotlight to Ophthalmology Growth Prospects - simplywall.st
Bausch + Lomb (NYSE:BLCO) Coverage Initiated at The Goldman Sachs Group - MarketBeat
Applying Elliott Wave Theory to Bausch + Lomb CorporationQuarterly Market Review & Comprehensive Market Scan Reports - newser.com
Why Bausch + Lomb Corporation stock is upgraded to buy2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - newser.com
Goldman Sachs Initiates Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Announces Target Price $16 - 富途牛牛
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating By Investing.com - Investing.com South Africa
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating - Investing.com
Is Zeal Aqua Limited a Smart Pick for Retirement PortfoliosEx-Dividend Date Alerts & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13 - BioSpace
Is Bausch + Lomb Corporation stock positioned for digital transformationMarket Growth Review & AI Driven Stock Reports - newser.com
Global Eye Health Leader Bausch + Lomb Announces Q3 Earnings Date and Strategic Investor Day Pipeline Review - Stock Titan
Will Bausch + Lomb Corporation stock benefit from Fed rate cutsBuy Signal & Real-Time Volume Surge Alerts - newser.com
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):